AIM ImmunoTech Inc. (AIM) News

AIM ImmunoTech Inc. (AIM): $0.38

0.00 (0.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AIM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 458

in industry

Filter AIM News Items

AIM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AIM News Highlights

  • AIM's 30 day story count now stands at 5.
  • Over the past 23 days, the trend for AIM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • NOV, SAFE and SITC are the most mentioned tickers in articles about AIM.

Latest AIM News From Around the Web

Below are the latest news stories about AIM IMMUNOTECH INC that investors may wish to consider to help them evaluate AIM as an investment opportunity.

AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022

OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced its abstract has been accepted for poster presentation at the British Society for Immunology Congress 2022 being held December 5-8, 2022 in Liverpool,

Yahoo | December 2, 2022

Maxim Group Remains a Buy on AIM ImmunoTech (AIM)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on AIM ImmunoTech (AIM - Research Report), with a price target of $3.00. The company's shares opened today at $0.50.McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and Adial Pharmaceuticals. According to TipRanks, McCarthy has an average return of -38.2% and a 16.67% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AIM ImmunoTech with a $3.00 average price target.

Catie Powers on TipRanks | November 16, 2022

AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update

– Company continues to execute and is well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones – Cash position expected to fund operations through end of 2023 OCALA, Fla., Nov. 15, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immune-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease ca

Yahoo | November 15, 2022

AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer

– Data selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting – Treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at 66%, comparable to pembrolizumab/neoadjuvant chemotherapy (NAC) – Planned Phase 2 study in early-stage TNBC to determine if CKM including Ampligen may be a safe and effective alternative to pembrolizumab or pembrolizumab/NAC OCALA, Fla., Nov.

Yahoo | November 14, 2022

AIM ImmunoTech Announces Corporate Governance Enhancements

OCALA, Fla., November 09, 2022--AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced the following corporate governance enhancements:

Yahoo | November 9, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Good morning, investor!

William White on InvestorPlace | November 7, 2022

AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting

OCALA, Fla., November 03, 2022--AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that shareholders have re-elected all three of the Company’s directors, Stewart L. Appelrouth, Thomas K. Equels and William M. Mitchell, at the Company’s Annual Meeting of Shareholders (the "Annual Meeting") held today.

Yahoo | November 3, 2022

AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease

Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity currently being evaluated for the treatment of globally important cancers, viral diseases and disorders of the immune system Ampligen has demonstrated positive results for the treatment of Ebola in previously conducted animal studies OCALA, Fla., Nov. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therape

Yahoo | November 2, 2022

Statement of the ASFV Committee on Ruling in Delaware Action

NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Jonathan Jorgl, an AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) stockholder, together with his nominees, Robert L. Chioini and Michael Rice (collectively, the “AIM Stockholder Full Value Committee” or the “ASFV Committee”), today announced that on October 28, 2022, the Delaware Court of Chancery found that Mr. Jorgl did not meet his burden of proving entitlement to mandatory injunctive relief, stating that factual questions prevented grant of judgm

Yahoo | November 1, 2022

Delaware Court Rules in Favor of AIM ImmunoTech and Declines to Declare Activist Group’s Nominations Valid

OCALA, Fla., October 31, 2022--AIM ImmunoTech Inc. (NYSE: American AIM) ("AIM" or the "Company") today announced that the Delaware Court of Chancery has denied Jonathan Jorgl’s motion for a mandatory preliminary injunction that sought to require the AIM Board of Directors (the "Board") to accept his director nominations and include his nominees on a universal proxy card for the upcoming Annual Meeting of Shareholders (the "Annual Meeting").

Yahoo | October 31, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7324 seconds.